Translation Animal Models of Diabetic Kidney Disease: Biochemical and Histological Phenotypes, Advantages and Limitations

References

• Akhtar M, Taha NM, Nauman A, Mujeeb IB, Al-Nabet A. Diabetic kidney disease: past and present. Adv Anat Pathol. 2020;27(2):87–97. doi:10.1097/PAP.0000000000000257
   PubMed Web of Science ®Google Scholar
• Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–1658. doi:10.2337/db08-1543
   PubMed Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308. doi:10.1681/ASN.2012070718
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312–2319. doi:10.1007/s00125-010-1860-3
   PubMed Web of Science ®Google Scholar
• Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81. doi:10.1038/nrneph.2015.173
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Khan SS, Quaggin SE. Therapies on the horizon for diabetic kidney disease. Curr Diab Rep. 2015;15(12):111. doi:10.1007/s11892-015-0685-3
   PubMed Web of Science ®Google Scholar
• Hu YY, Ye SD. Experimental models of type 2 diabetic nephropathy. Chin Med J. 2013;126(3):574–577.
   PubMed Web of Science ®Google Scholar
• Lee TN, Alborn WE, Knierman MD, Konrad RJ. The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochem Pharmacol. 2006;72(6):710–718. doi:10.1016/j.bcp.2006.06.005
   PubMed Web of Science ®Google Scholar
• Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537–546.
   PubMed Web of Science ®Google Scholar
• Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015;70(1):547 1–547 20. doi:10.1002/0471141755.ph0547s70
   Google Scholar
• Dufrane D, van Steenberghe M, Guiot Y, Goebbels RM, Saliez A, Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006;81(1):36–45. doi:10.1097/01.tp.0000189712.74495.82
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes. 2007;56(7):1825–1833. doi:10.2337/db06-1226
   PubMed Web of Science ®Google Scholar
• Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology. 2007;12(3):261–266. doi:10.1111/j.1440-1797.2007.00796.x
   PubMed Web of Science ®Google Scholar
• Betz B, Conway BR. An update on the use of animal models in diabetic nephropathy research. Curr Diab Rep. 2016;16(2):18. doi:10.1007/s11892-015-0706-2
   PubMed Web of Science ®Google Scholar
• Zamboni F, Cengiz IF, Barbosa AM, et al. Towards the development of a female animal model of T1DM using hyaluronic acid nanocoated cell transplantation: refinements and considerations for future protocols. Pharmaceutics. 2021;13(11). doi:10.3390/pharmaceutics13111925
   Web of Science ®Google Scholar
• Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol. 2006;290(1):F214–F222. doi:10.1152/ajprenal.00204.2005
   PubMed Web of Science ®Google Scholar
• Zheng C, Huang L, Luo W, et al. Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. Cell Death Dis. 2019;10(11):848. doi:10.1038/s41419-019-2085-0
   PubMedGoogle Scholar
• Liu XQ, Jiang L, Li YY, et al. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease. Acta Pharmacol Sin. 2022;43(1):96–110. doi:10.1038/s41401-021-00721-5
   PubMed Web of Science ®Google Scholar
• Zheng X, Soroush F, Long J, et al. Murine glomerular transcriptome links endothelial cell-specific molecule-1 deficiency with susceptibility to diabetic nephropathy. PLoS One. 2017;12(9):e0185250. doi:10.1371/journal.pone.0185250
   PubMed Web of Science ®Google Scholar
• Liu H, Takagaki Y, Kumagai A, Kanasaki K, Koya D. The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1α accumulation. J Diabetes Investig. 2021;12(5):697–709. doi:10.1111/jdi.13478
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Takagi S, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. 2020;5(6). doi:10.1172/jci.insight.129034
   Web of Science ®Google Scholar
• Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120–2131. doi:10.2337/db13-1029
   PubMed Web of Science ®Google Scholar
• Ilatovskaya DV, Blass G, Palygin O, et al. A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J Am Soc Nephrol. 2018;29(7):1917–1927. doi:10.1681/ASN.2018030280
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xie F, Lv X, et al. Mefunidone ameliorates diabetic kidney disease in STZ and db/db mice. FASEB J. 2021;35(1):e21198. doi:10.1096/fj.202001138RR
   PubMed Web of Science ®Google Scholar
• Malik S, Suchal K, Khan SI, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-kappaB-TNF-alpha and TGF-beta1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. 2017;313(2):F414–F422. doi:10.1152/ajprenal.00393.2016
   PubMed Web of Science ®Google Scholar
• Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336. doi:10.1186/s13287-020-01852-y
   PubMed Web of Science ®Google Scholar
• Zhu L, Han J, Yuan R, Xue L, Pang W. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-kappaB pathway. Biol Res. 2018;51(1):9. doi:10.1186/s40659-018-0157-8
   PubMedGoogle Scholar
• Giralt-Lopez A, Molina-Van den Bosch M, Vergara A, et al. Revisiting experimental models of diabetic nephropathy. Int J Mol Sci. 2020;21(10). doi:10.3390/ijms21103587
   PubMed Web of Science ®Google Scholar
• Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DC. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int. 2005;68(1):391–398. doi:10.1111/j.1523-1755.2005.00405.x
   PubMed Web of Science ®Google Scholar
• Kraynak AR, Storer RD, Jensen RD, et al. Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol Appl Pharmacol. 1995;135(2):279–286. doi:10.1006/taap.1995.1234
   PubMed Web of Science ®Google Scholar
• Bayrasheva VK, Babenko AY, Dobronravov VA, et al. Uninephrectomized high-fat-fed nicotinamide-streptozotocin-induced diabetic rats: a model for the investigation of diabetic nephropathy in type 2 diabetes. J Diabetes Res. 2016;2016:8317850. doi:10.1155/2016/8317850
   PubMed Web of Science ®Google Scholar
• Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. Pediatr Nephrol. 2014;29(2):193–202. doi:10.1007/s00467-013-2494-8
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57(5):1803–1817. doi:10.1046/j.1523-1755.2000.00031.x
   PubMed Web of Science ®Google Scholar
• Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int. 1997;51(5):1553–1567. doi:10.1038/ki.1997.214
   PubMed Web of Science ®Google Scholar
• Abrass CK. Diabetic nephropathy. Mechanisms of mesangial matrix expansion. West J Med. 1995;162(4):318–321.
   PubMedGoogle Scholar
• Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38(3 Pt 2):635–638. doi:10.1161/hy09t1.094234
   PubMed Web of Science ®Google Scholar
• Uil M, Scantlebery AML, Butter LM, et al. Author correction: combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the ‘resistant’ C57Bl/6J mouse strain. Sci Rep. 2019;9(1):3425. doi:10.1038/s41598-018-38075-4
   PubMedGoogle Scholar
• Wada J, Zhang H, Tsuchiyama Y, et al. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis. Kidney Int. 2001;59(4):1363–1373. doi:10.1046/j.1523-1755.2001.0590041363.x
   PubMed Web of Science ®Google Scholar
• Mao ZM, Shen SM, Wan YG, et al. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid. J Ethnopharmacol. 2015;173:256–265. doi:10.1016/j.jep.2015.07.036
   PubMed Web of Science ®Google Scholar
• Liu BC, Huang HQ, Luo DD, Ma KL, Liu DG, Liu H. Connective tissue growth factor is associated with the early renal hypertrophy in uninephrectomized diabetic rats. Chin Med J. 2006;119(12):1010–1016.
   PubMed Web of Science ®Google Scholar
• Inada Y, Murakami M, Tazawa S, Akahane M. KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2000;27(4):270–276. doi:10.1046/j.1440-1681.2000.03235.x
   PubMed Web of Science ®Google Scholar
• Li D, Lu Z, Jia J, Zheng Z, Lin S. MiR-124 is related to podocytic adhesive capacity damage in STZ-induced uninephrectomized diabetic rats. Kidney Blood Press Res. 2013;37(4–5):422–431. doi:10.1159/000355721
   PubMed Web of Science ®Google Scholar
• Gurley SB, Mach CL, Stegbauer J, et al. Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol. 2010;298(3):F788–F795. doi:10.1152/ajprenal.90515.2008
   PubMed Web of Science ®Google Scholar
• Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–233.
   PubMed Web of Science ®Google Scholar
• Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53(10):2093–2104. doi:10.1007/s00125-010-1794-9
   PubMed Web of Science ®Google Scholar
• Fujita H, Fujishima H, Chida S, et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol. 2009;20(6):1303–1313. doi:10.1681/asn.2008080844
   PubMed Web of Science ®Google Scholar
• Yu L, Su Y, Paueksakon P, et al. Integrin α1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy. Kidney Int. 2012;81(11):1086–1097. doi:10.1038/ki.2011.474
   PubMed Web of Science ®Google Scholar
• Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell. 1989;58(6):1067–1073. doi:10.1016/0092-8674(89)90505-9
   PubMed Web of Science ®Google Scholar
• Zheng S, Noonan WT, Metreveli NS, et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes. 2004;53(12):3248–3257. doi:10.2337/diabetes.53.12.3248
   PubMed Web of Science ®Google Scholar
• Zheng S, Huang Y, Yang L, Chen T, Xu J, Epstein PN. Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration and changes in gene expression. Nephron Exp Nephrol. 2011;119(1):e21–e32. doi:10.1159/000327586
   PubMedGoogle Scholar
• Wang W, Jiang S, Tang X, et al. Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165589. doi:10.1016/j.bbadis.2019.165589
   PubMed Web of Science ®Google Scholar
• Hsu JD, Wu CC, Hung CN, Wang CJ, Huang HP. Myrciaria cauliflora extract improves diabetic nephropathy via suppression of oxidative stress and inflammation in streptozotocin-nicotinamide mice. J Food Drug Anal. 2016;24(4):730–737. doi:10.1016/j.jfda.2016.03.009
   PubMed Web of Science ®Google Scholar
• Perez Gutierrez RM, Garcia Campoy AH, Paredes Carrera SP, Muniz Ramirez A, Mota Flores JM, Flores Valle SO. 3’-O-beta-d-glucopyranosyl-alpha,4,2’,4’,6’-pentahydroxy-dihydrochalcone, from bark of eysenhardtia polystachya prevents diabetic nephropathy via inhibiting protein glycation in STZ-nicotinamide induced diabetic mice. Molecules. 2019;24(7). doi:10.3390/molecules24071214
   PubMed Web of Science ®Google Scholar
• Abd El Motteleb DM, Abd El Aleem DI. Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: insights in the underlying mechanisms. Clin Exp Pharmacol Physiol. 2017;44(4):509–521. doi:10.1111/1440-1681.12729
   PubMed Web of Science ®Google Scholar
• Chandran R, George BP, Abrahamse H, Parimelazhagan T. Therapeutic effects of Syzygium mundagam bark methanol extract on type-2 diabetic complications in rats. Biomed Pharmacother. 2017;95:167–174. doi:10.1016/j.biopha.2017.08.061
   PubMed Web of Science ®Google Scholar
• Corremans R, D’Haese PC, Vervaet BA, Verhulst A. L-NAME administration enhances diabetic kidney disease development in an STZ/NAD rat model. Int J Mol Sci. 2021;22(23). doi:10.3390/ijms222312767
   PubMed Web of Science ®Google Scholar
• Kishore L, Kaur N, Singh R. Renoprotective effect of Bacopa monnieri via inhibition of advanced glycation end products and oxidative stress in STZ-nicotinamide-induced diabetic nephropathy. Ren Fail. 2016;38(9):1528–1544. doi:10.1080/0886022X.2016.1227920
   PubMed Web of Science ®Google Scholar
• Maheshwari RA, Balaraman R, Sen AK, Seth AK. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats. Indian J Pharmacol. 2014;46(6):627–632. doi:10.4103/0253-7613.144924
   PubMed Web of Science ®Google Scholar
• Rai U, Kosuru R, Prakash S, Tiwari V, Singh S. Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats. Eur J Pharmacol. 2019;865:172763. doi:10.1016/j.ejphar.2019.172763
   PubMed Web of Science ®Google Scholar
• Sathibabu Uddandrao VV, Brahmanaidu P, Ravindarnaik R, Suresh P, Vadivukkarasi S, Saravanan G. Restorative potentiality of S-allylcysteine against diabetic nephropathy through attenuation of oxidative stress and inflammation in streptozotocin-nicotinamide-induced diabetic rats. Eur J Nutr. 2019;58(6):2425–2437. doi:10.1007/s00394-018-1795-x
   PubMed Web of Science ®Google Scholar
• Yan LJ. The nicotinamide/streptozotocin rodent model of type 2 diabetes: renal pathophysiology and redox imbalance features. Biomolecules. 2022;12(9). doi:10.3390/biom12091225
   Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Lee ES, Kwon MH, Kim HM, et al. Dibenzoylmethane ameliorates lipid-induced inflammation and oxidative injury in diabetic nephropathy. J Endocrinol. 2019;240(2):169–179. doi:10.1530/JOE-18-0206
   PubMed Web of Science ®Google Scholar
• Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. 2007;15(4):798–808. doi:10.1038/oby.2007.608
   PubMed Web of Science ®Google Scholar
• Samane S, Christon R, Dombrowski L, et al. Fish oil and argan oil intake differently modulate insulin resistance and glucose intolerance in a rat model of dietary-induced obesity. Metabolism. 2009;58(7):909–919. doi:10.1016/j.metabol.2009.02.013
   PubMed Web of Science ®Google Scholar
• Sangartit W, Ha KB, Lee ES, et al. Tetrahydrocurcumin ameliorates kidney injury and high systolic blood pressure in high-fat diet-induced type 2 diabetic mice. Endocrinol Metab. 2021;36(4):810–822. doi:10.3803/EnM.2021.988
   Google Scholar
• Lee ES, Kang JS, Kim HM, et al. Dehydrozingerone inhibits renal lipotoxicity in high-fat diet-induced obese mice. J Cell Mol Med. 2021;25(18):8725–8733. doi:10.1111/jcmm.16828
   PubMed Web of Science ®Google Scholar
• Locatelli M, Macconi D, Corna D, et al. Sirtuin 3 deficiency aggravates kidney disease in response to high-fat diet through lipotoxicity-induced mitochondrial damage. Int J Mol Sci. 2022;23(15). doi:10.3390/ijms23158345
   Web of Science ®Google Scholar
• Nunes S, Alves A, Preguica I, et al. Crescent-like lesions as an early signature of nephropathy in a rat model of prediabetes induced by a hypercaloric diet. Nutrients. 2020;12(4). doi:10.3390/nu12040881
   Web of Science ®Google Scholar
• Liu Y, Wang Z, Yin W, et al. Severe insulin resistance and moderate glomerulosclerosis in a minipig model induced by high-fat/ high-sucrose/ high-cholesterol diet. Exp Anim. 2007;56(1):11–20. doi:10.1538/expanim.56.11
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Wang S, Yin W, Wang Z. Ibrolipim attenuates early-stage nephropathy in diet-induced diabetic minipigs: focus on oxidative stress and fibrogenesis. Biomed Pharmacother. 2020;129:110321. doi:10.1016/j.biopha.2020.110321
   PubMed Web of Science ®Google Scholar
• Bakker PJ, Butter LM, Kors L, et al. Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation. Kidney Int. 2014;85(5):1112–1122. doi:10.1038/ki.2013.503
   PubMed Web of Science ®Google Scholar
• Panasevich MR, Meers GM, Linden MA, et al. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. Am J Physiol Endocrinol Metab. 2018;314(1):E78–E92. doi:10.1152/ajpendo.00015.2017
   PubMed Web of Science ®Google Scholar
• Feng Y, Yang S, Ma Y, Bai XY, Chen X. Role of Toll-like receptors in diabetic renal lesions in a miniature pig model. Sci Adv. 2015;1(5):e1400183. doi:10.1126/sciadv.1400183
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li XH, Chen HY, Jin QY. The effects of compound centella formula on OxInflammation and silent information regulator 1 in a high-fat diet/streptozotocin-induced diabetic kidney disease rat model. Exp Ther Med. 2021;22(3):962. doi:10.3892/etm.2021.10394
   PubMed Web of Science ®Google Scholar
• Wang Z, Fu W, Huo M, et al. Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging. Acta Pharm Sin B. 2021;11(11):3665–3677. doi:10.1016/j.apsb.2021.05.013
   PubMed Web of Science ®Google Scholar
• Wu T, Yang X, Cong Y, et al. Effects of Qidantang Granule on early stage of diabetic kidney disease in rats. Aging. 2022;14(11):4888–4896. doi:10.18632/aging.204121
   PubMedGoogle Scholar
• Chen HW, Yang MY, Hung TW, Chang YC, Wang CJ. Nelumbo nucifera leaves extract attenuate the pathological progression of diabetic nephropathy in high-fat diet-fed and streptozotocin-induced diabetic rats. J Food Drug Anal. 2019;27(3):736–748. doi:10.1016/j.jfda.2018.12.009
   PubMed Web of Science ®Google Scholar
• Huang W, Man Y, Gao C, et al. Short-chain fatty acids ameliorate diabetic nephropathy via GPR43-mediated inhibition of oxidative stress and NF-kappaB signaling. Oxid Med Cell Longev. 2020;2020:4074832. doi:10.1155/2020/4074832
   PubMed Web of Science ®Google Scholar
• Kim DH, Choi BH, Ku SK, Park JH, Oh E, Kwak MK. Beneficial effects of sarpogrelate and rosuvastatin in high fat diet/streptozotocin-induced nephropathy in mice. PLoS One. 2016;11(4):e0153965. doi:10.1371/journal.pone.0153965
   PubMed Web of Science ®Google Scholar
• Song W, Wei L, Du Y, Wang Y, Jiang S. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-kappaB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Int ImmunopharmacoL. 2018;63:227–238. doi:10.1016/j.intimp.2018.07.027
   PubMed Web of Science ®Google Scholar
• Han J, Pang X, Shi X, Zhang Y, Peng Z, Xing Y. Ginkgo biloba extract EGB761 ameliorates the extracellular matrix accumulation and mesenchymal transformation of renal tubules in diabetic kidney disease by inhibiting endoplasmic reticulum stress. Biomed Res Int. 2021;2021:6657206. doi:10.1155/2021/6657206
   PubMed Web of Science ®Google Scholar
• Han YC, Tang SQ, Liu YT, et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis. 2021;12(10):925. doi:10.1038/s41419-021-04184-8
   PubMed Web of Science ®Google Scholar
• An X, Zhang Y, Cao Y, Chen J, Qin H, Yang L. Punicalagin protects diabetic nephropathy by inhibiting pyroptosis based on TXNIP/NLRP3 pathway. Nutrients. 2020;12(5). doi:10.3390/nu12051516
   Web of Science ®Google Scholar
• Li Y, Xue M, Hu F, et al. Klotho prevents epithelial-mesenchymal transition through Egr-1 downregulation in diabetic kidney disease. BMJ Open Diabetes Res Care. 2021;9(1). doi:10.1136/bmjdrc-2020-002038
   Web of Science ®Google Scholar
• Glastras SJ, Chen H, Teh R, et al. Mouse models of diabetes, obesity and related kidney disease. PLoS One. 2016;11(8):e0162131. doi:10.1371/journal.pone.0162131
   PubMed Web of Science ®Google Scholar
• Hakim ZS, Patel BK, Goyal RK. Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats. Indian J Physiol Pharmacol. 1997;41(4):353–360.
   PubMedGoogle Scholar
• Rajkumar L, Srinivasan N, Balasubramanian K, Govindarajulu P. Increased degradation of dermal collagen in diabetic rats. Indian J Exp Biol. 1991;29(11):1081–1083.
   PubMedGoogle Scholar
• Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 diabetes--related traits in mouse strains susceptible to diet-induced obesity. Diabetes. 2003;52(8):1958–1966. doi:10.2337/diabetes.52.8.1958
   PubMed Web of Science ®Google Scholar
• Sugano M, Yamato H, Hayashi T, et al. High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis. 2006;16(7):477–484. doi:10.1016/j.numecd.2005.08.007
   PubMed Web of Science ®Google Scholar
• Dusabimana T, Park EJ, Je J, et al. Geniposide improves diabetic nephropathy by enhancing ULK1-mediated autophagy and reducing oxidative stress through AMPK activation. Int J Mol Sci. 2021;22(4). doi:10.3390/ijms22041651
   Web of Science ®Google Scholar
• Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41(11):1422–1428. doi:10.2337/diab.41.11.1422
   PubMed Web of Science ®Google Scholar
• Shin JH, So BI, Song YS, et al. Histopathological analyses of diabetic nephropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Endocr Res. 2015;40(1):29–36. doi:10.3109/07435800.2014.915848
   PubMed Web of Science ®Google Scholar
• Kawano K, Mori S, Hirashima T, Man ZW, Natori T. Examination of the pathogenesis of diabetic nephropathy in OLETF rats. J Vet Med Sci. 1999;61(11):1219–1228. doi:10.1292/jvms.61.1219
   PubMed Web of Science ®Google Scholar
• Nozako M, Koyama T, Nagano C, et al. An atherogenic paigen-diet aggravates nephropathy in type 2 diabetic OLETF rats. PLoS One. 2015;10(11):e0143979. doi:10.1371/journal.pone.0143979
   PubMed Web of Science ®Google Scholar
• Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med. 1976;119(1):85–90. doi:10.1620/tjem.119.85
   PubMed Web of Science ®Google Scholar
• Movassat J, Saulnier C, Serradas P, Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia. 1997;40(8):916–925. doi:10.1007/s001250050768
   PubMed Web of Science ®Google Scholar
• Ismail I, Lewis M, Peters JR, Scanlon MF. Hypothalamic mediation of reduced GH secretion in diabetic rats: evidence for reduced cholinergic inhibition of somatostatin release. J Neuroendocrinol. 1995;7(4):311–318. doi:10.1111/j.1365-2826.1995.tb00763.x
   PubMed Web of Science ®Google Scholar
• Ostenson CG, Khan A, Abdel-Halim SM, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia. 1993;36(1):3–8. doi:10.1007/bf00399086
   PubMed Web of Science ®Google Scholar
• Bisbis S, Bailbe D, Tormo MA, et al. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am J Physiol. 1993;265(5 Pt 1):E807–E813. doi:10.1152/ajpendo.1993.265.5.E807
   PubMedGoogle Scholar
• Picarel-Blanchot F, Berthelier C, Bailbé D, Portha B. Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. Am J Physiol. 1996;271(4 Pt 1):E755–E762. doi:10.1152/ajpendo.1996.271.4.E755
   PubMedGoogle Scholar
• Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 2003;63(6):2162–2170. doi:10.1046/j.1523-1755.2003.00007.x
   PubMed Web of Science ®Google Scholar
• Phillips AO, Baboolal K, Riley S, et al. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the goto kakizaki model of non–insulin-dependent diabetes mellitus. Am J Kidney Dis. 2001;37(2):400–410. doi:10.1053/ajkd.2001.21322
   PubMed Web of Science ®Google Scholar
• Sato N, Komatsu K, Kurumatani H. Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol. 2003;23(5):334–342. doi:10.1159/000072915
   PubMed Web of Science ®Google Scholar
• Olearczyk JJ, Quigley JE, Mitchell BC, et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto–Kakizaki rats. Clin Sci. 2009;116(1):61–70. doi:10.1042/cs20080039
   Web of Science ®Google Scholar
• Kuwabara WMT, Panveloski-Costa AC, Yokota CNF, et al. Comparison of Goto-Kakizaki rats and high fat diet-induced obese rats: are they reliable models to study Type 2 diabetes mellitus? PLoS One. 2017;12(12):e0189622. doi:10.1371/journal.pone.0189622
   PubMed Web of Science ®Google Scholar
• Suriano F, Vieira-Silva S, Falony G, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021;9(1):147. doi:10.1186/s40168-021-01097-8
   PubMed Web of Science ®Google Scholar
• Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 2005;54(9):2628–2637. doi:10.2337/diabetes.54.9.2628
   PubMed Web of Science ®Google Scholar
• Hudkins KL, Pichaiwong W, Wietecha T, et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol. 2010;21(9):1533–1542. doi:10.1681/asn.2009121290
   PubMed Web of Science ®Google Scholar
• Björnson Granqvist A, Ericsson A, Sanchez J, et al. High-protein diet accelerates diabetes and kidney disease in the BTBR ob/ob mouse. Am J Physiol Renal Physiol. 2020;318(3):F763–F771. doi:10.1152/ajprenal.00484.2019
   PubMed Web of Science ®Google Scholar
• Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2011;20(3):278–284. doi:10.1097/MNH.0b013e3283451901
   PubMed Web of Science ®Google Scholar
• Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153(3740):1127–1128. doi:10.1126/science.153.3740.1127
   PubMed Web of Science ®Google Scholar
• Mao HZ, Roussos ET, Péterfy M. Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains. Biochim Biophys Acta. 2006;1762(4):440–446. doi:10.1016/j.bbadis.2006.01.002
   PubMed Web of Science ®Google Scholar
• Mizunuma Y, Kanasaki K, Nitta K, et al. CD-1(db/db) mice: a novel type 2 diabetic mouse model with progressive kidney fibrosis. J Diabetes Investig. 2020;11(6):1470–1481. doi:10.1111/jdi.13311
   PubMed Web of Science ®Google Scholar
• Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284(6):F1138–F1144. doi:10.1152/ajprenal.00315.2002
   PubMed Web of Science ®Google Scholar
• Østergaard MV, Pinto V, Stevenson K, Worm J, Fink LN, Coward RJ. DBA2J db/db mice are susceptible to early albuminuria and glomerulosclerosis that correlate with systemic insulin resistance. Am J Physiol Renal Physiol. 2017;312(2):F312–F321. doi:10.1152/ajprenal.00451.2016
   PubMed Web of Science ®Google Scholar
• Boquist L, Hellman B, Lernmark A, Täljedal IB. Influence of the mutation “diabetes” on insulin release and islet morphology in mice of different genetic backgrounds. J Cell Biol. 1974;62(1):77–89. doi:10.1083/jcb.62.1.77
   PubMed Web of Science ®Google Scholar
• Meade CJ, Brandon DR, Smith W, Simmonds RG, Harris S, Sowter C. The relationship between hyperglycaemia and renal immune complex deposition in mice with inherited diabetes. Clin Exp Immunol. 1981;43(1):109–120.
   PubMed Web of Science ®Google Scholar
• Zhang HM, Dang H, Kamat A, Yeh CK, Zhang BX. Geldanamycin derivative ameliorates high fat diet-induced renal failure in diabetes. PLoS One. 2012;7(3):e32746. doi:10.1371/journal.pone.0032746
   PubMed Web of Science ®Google Scholar
• Nørgaard SA, Briand F, Sand FW, et al. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. Eur J Pharmacol. 2019;860:172537. doi:10.1016/j.ejphar.2019.172537
   PubMed Web of Science ®Google Scholar
• Maekawa M, Maekawa T, Sasase T, et al. Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. Physiol Res. 2022;71(2):209–217. doi:10.33549/physiolres.934784
   PubMed Web of Science ®Google Scholar
• Aibara Y, Nakashima A, Kawano KI, et al. Daily low-intensity pulsed ultrasound ameliorates renal fibrosis and inflammation in experimental hypertensive and diabetic nephropathy. Hypertension. 2020;76(6):1906–1914. doi:10.1161/hypertensionaha.120.15237
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang T, Li J, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005;54(8):2328–2335. doi:10.2337/diabetes.54.8.2328
   PubMed Web of Science ®Google Scholar
• Vora JP, Zimsen SM, Houghton DC, Anderson S. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol. 1996;7(1):113–117. doi:10.1681/asn.V71113
   PubMed Web of Science ®Google Scholar
• Tokuyama Y, Sturis J, DePaoli AM, et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44(12):1447–1457. doi:10.2337/diab.44.12.1447
   PubMed Web of Science ®Google Scholar
• Kubota M, Watanabe R, Yamaguchi M, et al. Rice endosperm protein slows progression of fatty liver and diabetic nephropathy in Zucker diabetic fatty rats. Br J Nutr. 2016;116(8):1326–1335. doi:10.1017/s0007114516003512
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu Q, Dai W, Hua B, Li H, Li W. Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats. Biomed Pharmacother. 2019;118:109346. doi:10.1016/j.biopha.2019.109346
   PubMed Web of Science ®Google Scholar
• Chander PN, Gealekman O, Brodsky SV, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol. 2004;15(9):2391–2403. doi:10.1097/01.Asn.0000135971.88164.2c
   PubMed Web of Science ®Google Scholar
• Kundu A, Gali S, Sharma S, et al. Tenovin-1 ameliorates renal fibrosis in high-fat-diet-induced diabetic nephropathy via antioxidant and anti-inflammatory pathways. Antioxidants. 2022;11(9). doi:10.3390/antiox11091812
   Web of Science ®Google Scholar
• Pugsley MK, Brooks MB, Fishman CE, et al. Use of the ZDF rat to model dietary fat induced hypercoagulability is limited by progressive and fatal nephropathy. J Pharmacol Toxicol Methods. 2021;107:106933. doi:10.1016/j.vascn.2020.106933
   PubMed Web of Science ®Google Scholar
• Siwy J, Zoja C, Klein J, et al. Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One. 2012;7(12):e51334. doi:10.1371/journal.pone.0051334
   PubMed Web of Science ®Google Scholar
• Tofovic SP, Kusaka H, Kost CK, Bastacky S. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail. 2000;22(4):387–406. doi:10.1081/jdi-100100882
   PubMed Web of Science ®Google Scholar
• Dower K, Zhao S, Schlerman FJ, et al. High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy. PLoS One. 2017;12(7):e0181861. doi:10.1371/journal.pone.0181861
   PubMed Web of Science ®Google Scholar
• Bilan VP, Salah EM, Bastacky S, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol. 2011;210(3):293–308. doi:10.1530/joe-11-0122
   PubMed Web of Science ®Google Scholar
• Zhang C, Dower K, Zhang B, Martinez RV, Lin LL, Zhao S. Computational identification and validation of alternative splicing in ZSF1 rat RNA-seq data, a preclinical model for type 2 diabetic nephropathy. Sci Rep. 2018;8(1):7624. doi:10.1038/s41598-018-26035-x
   PubMedGoogle Scholar
• Taketomi S, Ikeda H, Ishikawa E, Iwatsuka H. Determination of overall insulin sensitivity in diabetic mice, KK. Horm Metab Res. 1982;14(1):14–18. doi:10.1055/s-2007-1018909
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang H, Gao R, Dynamic Phenotypes LY. Molecular mechanisms to understand the pathogenesis of diabetic nephropathy in two widely used animal models of type 2 diabetes mellitus. Front Cell Dev Biol. 2020;8:172. doi:10.3389/fcell.2020.00172
   PubMed Web of Science ®Google Scholar
• Mori Y, Ajay AK, Chang JH, et al. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab. 2021;33(5):1042–1061.e7. doi:10.1016/j.cmet.2021.04.004
   PubMed Web of Science ®Google Scholar
• Ito T, Tanimoto M, Yamada K, et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology. 2006;11(1):29–35. doi:10.1111/j.1440-1797.2006.00543.x
   PubMed Web of Science ®Google Scholar
• Oda K, Miyamoto S, Kodera R, Wada J, Shikata K. Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice. J Diabetes Investig. 2023;14(2):205–220. doi:10.1111/jdi.13930
   PubMed Web of Science ®Google Scholar
• Nobrega MA, Fleming S, Roman RJ, et al. Initial characterization of a rat model of diabetic nephropathy. Diabetes. 2004;53(3):735–742. doi:10.2337/diabetes.53.3.735
   PubMed Web of Science ®Google Scholar
• Kojima N, Slaughter TN, Paige A, Kato S, Roman RJ, Williams JM. Comparison of the development diabetic induced renal disease in strains of goto-kakizaki rats. J Diabetes Metab. 2013;Suppl 9(5). doi:10.4172/2155-6156.S9-005
   PubMedGoogle Scholar
• Palygin O, Spires D, Levchenko V, et al. Progression of diabetic kidney disease in T2DN rats. Am J Physiol Renal Physiol. 2019;317(6):F1450–F1461. doi:10.1152/ajprenal.00246.2019
   PubMed Web of Science ®Google Scholar
• Spires DR, Palygin O, Levchenko V, et al. Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats. Physiol Genomics. 2021;53(6):223–234. doi:10.1152/physiolgenomics.00009.2021
   PubMed Web of Science ®Google Scholar
• Sessa WC. eNOS at a glance. J Cell Sci. 2004;117(Pt 12):2427–2429. doi:10.1242/jcs.01165
   PubMed Web of Science ®Google Scholar
• Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, Malik AB. Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol. 2005;289(3):L371–L381. doi:10.1152/ajplung.00175.2004
   PubMed Web of Science ®Google Scholar
• Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004;24(4):333–344. doi:10.1016/j.semnephrol.2004.04.005
   PubMed Web of Science ®Google Scholar
• Hiragushi K, Sugimoto H, Shikata K, et al. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract. 2001;53(3):149–159. doi:10.1016/s0168-8227(01)00260-1
   PubMed Web of Science ®Google Scholar
• Oe Y, Miyazaki M, Takahashi N. Coagulation, protease-activated receptors, and diabetic kidney disease: lessons from eNOS-deficient mice. Tohoku J Exp Med. 2021;255(1):1–8. doi:10.1620/tjem.255.1
   PubMed Web of Science ®Google Scholar
• Yamada K, Nakano H, Nakayama M, et al. Endothelium-dependent relaxation in peripheral vasculature and kidney of non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1995;9(4):203–207. doi:10.1016/1056-8727(95)80002-v
   PubMed Web of Science ®Google Scholar
• Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006;17(10):2664–2669. doi:10.1681/asn.2006070798
   PubMed Web of Science ®Google Scholar
• Mohan S, Reddick RL, Musi N, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest. 2008;88(5):515–528. doi:10.1038/labinvest.2008.23
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18(2):539–550. doi:10.1681/asn.2006050459
   PubMed Web of Science ®Google Scholar
• Dschietzig TB, Krause-Relle K, Hennequin M, et al. Relaxin-2 does not ameliorate nephropathy in an experimental model of type-1 diabetes. Kidney Blood Press Res. 2015;40(1):77–88. doi:10.1159/000368484
   PubMed Web of Science ®Google Scholar
• Kosugi T, Heinig M, Nakayama T, Matsuo S, Nakagawa T. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol. 2010;176(2):619–629. doi:10.2353/ajpath.2010.090578
   PubMed Web of Science ®Google Scholar
• Shi Y, Huang C, Zhao Y, et al. RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy. Sci Rep. 2020;10(1):10458. doi:10.1038/s41598-020-67054-x
   PubMed Web of Science ®Google Scholar
• Harloff M, Prüschenk S, Seifert R, Schlossmann J. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice. Br J Pharmacol. 2022;179(11):2460–2475. doi:10.1111/bph.15425
   PubMed Web of Science ®Google Scholar
• Yuen DA, Stead BE, Zhang Y, et al. eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol. 2012;23(11):1810–1823. doi:10.1681/asn.2011121170
   PubMed Web of Science ®Google Scholar
• Kanetsuna Y, Takahashi K, Nagata M, et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol. 2007;170(5):1473–1484. doi:10.2353/ajpath.2007.060481
   PubMed Web of Science ®Google Scholar
• Li F, Wang CH, Wang JG, et al. Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet. J Thromb Haemost. 2010;8(10):2122–2132. doi:10.1111/j.1538-7836.2010.03976.x
   PubMed Web of Science ®Google Scholar
• Li Y, Chung S, Li Z, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018;3(10). doi:10.1172/jci.insight.120365
   Web of Science ®Google Scholar
• Stec DF, Wang S, Stothers C, et al. Alterations of urinary metabolite profile in model diabetic nephropathy. Biochem Biophys Res Commun. 2015;456(2):610–614. doi:10.1016/j.bbrc.2014.12.003
   PubMed Web of Science ®Google Scholar
• Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci. 2018;132(16):1811–1836. doi:10.1042/cs20171459
   PubMed Web of Science ®Google Scholar
• Chen C, Wang C, Hu C, et al. Normoalbuminuric diabetic kidney disease. Front Med. 2017;11(3):310–318. doi:10.1007/s11684-017-0542-7
   PubMed Web of Science ®Google Scholar
• Bornfeldt KE, Kramer F, Batorsky A, et al. A novel type 2 diabetes mouse model of combined diabetic kidney disease and atherosclerosis. Am J Pathol. 2018;188(2):343–352. doi:10.1016/j.ajpath.2017.10.012
   PubMed Web of Science ®Google Scholar
• Tsalamandris C, Allen TJ, Gilbert RE, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43(5):649–655. doi:10.2337/diab.43.5.649
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97–111. doi:10.2337/diaclin.33.2.97
   PubMedGoogle Scholar
• Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32(3):404–419.e6. doi:10.1016/j.cmet.2020.06.020
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang CG, Wang XH, Liu DH. Progression of atherosclerosis in ApoE-knockout mice fed on a high-fat diet. Eur Rev Med Pharmacol Sci. 2016;20(18):3863–3867.
   PubMed Web of Science ®Google Scholar